| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement | Journal of Hepatology | 2020 | 764 |
| ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment | Journal of Crohn's and Colitis | 2020 | 320 |
| Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial | JAMA Oncology | 2020 | 274 |
| ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment | Journal of Crohn's and Colitis | 2020 | 122 |
| The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology | Journal of Hepatology | 2020 | 108 |
| Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF | Journal of Hepatology | 2020 | 102 |
| A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis | Journal of Hepatology | 2020 | 88 |
| Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020 | Endoscopy | 2020 | 77 |
| Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease | Gastroenterology | 2020 | 75 |
| Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis | Gastroenterology | 2020 | 66 |
| Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension | Journal of Hepatology | 2020 | 65 |
| Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis | Gastroenterology | 2020 | 63 |
| Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. | Journal of Clinical Oncology | 2020 | 62 |
| Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma | Hepatology | 2020 | 62 |
| Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS | Journal of Hepatology | 2020 | 52 |
| Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease | Inflammatory Bowel Diseases | 2020 | 43 |
| Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial | The Lancet Gastroenterology and Hepatology | 2020 | 43 |
| Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS | Journal of Clinical Endocrinology and Metabolism | 2020 | 43 |
| Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis | Journal of Hepatology | 2020 | 41 |
| The cryo-EM structure of African swine fever virus unravels a unique architecture comprising two icosahedral protein capsids and two lipoprotein membranes | Journal of Biological Chemistry | 2020 | 41 |
| Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis | Clinical Gastroenterology and Hepatology | 2020 | 41 |
| Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study | Hepatology | 2020 | 40 |
| Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting | Gut | 2020 | 39 |
| Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme | Journal of Crohn's and Colitis | 2020 | 35 |
| Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation | Nature Communications | 2020 | 34 |
